|Bid||280.21 x 900|
|Ask||285.00 x 800|
|Day's Range||276.03 - 282.08|
|52 Week Range||223.25 - 363.92|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||14.53|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)
View more earnings on BIIBSee more from BenzingaClick here for options trades from BenzingaBiogen Buys Acute Ischemic Stroke Candidate For One-Time Payment Of MBiogen, Capsigen Ink .3B AAV Capsids Development Pact For CNS & Neuromuscular Disorders© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Biogen Inc's experimental gene therapy for a genetic retinal disease that leads to progressive vision loss did not meet the main goal of a mid-to-late stage study, the drugmaker said on Friday. The treatment, BIIB112, did not show significant improvement in retinal sensitivity in patients with X-linked retinitis pigmentosa, a rare eye condition that has no approved treatments. The drug, however, showed positive trends in improving visual acuity under low light conditions and Biogen is analyzing the complete data from the study to figure out next steps.